Goldman Sachs Maintains Buy Rating on Viridian Therapeutics
Goldman Sachs has reaffirmed its Buy rating on Viridian Therapeutics (NASDAQ: VRDN) and confirmed a price target of $31.00. This confidence is largely based on the anticipated results from the Phase 3 THRIVE-2 study, which is set to unveil data regarding the treatment of chronic thyroid eye disease (TED) by the end of 2024. This study concentrates on Velogrotug (veli), a promising drug that previously demonstrated effective outcomes in the active TED THRIVE trial presented recently.
Significance of THRIVE-2 Study Results
The management of Viridian is optimistic that the THRIVE-2 Phase 3 results will mirror those from previous studies, particularly the Phase 4 chronic study for Tepezza, another approved TED treatment. However, the specifics on expectations concerning proptosis response and other outcome measures were not fully detailed. Variations noted in proptosis responses in Tepezza's results, along with differing inclusion criteria, dilute the ease of making direct comparisons. Essentially, the THRIVE study is pivotal for defining the benefit-risk profile of veli, while the results from THRIVE-2 are crucial for compiling the Biologics License Application (BLA).
Potential Outcomes and Market Expectations
According to Goldman Sachs, successful results from the THRIVE trial lessen risks associated with the THRIVE-2 study and highlight the potential for veli to surpass Tepezza in efficacy. They predict that the veli could show a placebo-adjusted proptosis response rate of approximately 40% or even higher and maintain a safety profile akin to that observed in the THRIVE study, where only about 5.5% of placebo-adjusted hearing adverse events (AEs) were reported. The anticipation surrounding these results is palpable among both the investment community and Viridian itself, as the outcomes could firmly position veli within the competitive TED treatment landscape.
Analyst Interest and Price Target Adjustments
Viridian Therapeutics has recently caught the attention of multiple analyst firms owing to the successful Phase 3 trial outcomes for veli. RBC Capital has lifted its price target for Viridian's shares from $35 to $44 while keeping an Outperform rating due to the favorable results of the drug in managing active TED. Alongside this, Goldman Sachs raised its price target on the stock from $25 to $31, continuing to provide a Buy rating.
Additional Analyst Ratings and Market Reactions
Needham has also revised its target on Viridian shares to $38, surpassing the previous target of $30, upholding a Buy rating. H.C. Wainwright reiterated its Buy rating while maintaining a price target of $27, whereas B. Riley upgraded its price target to $22 while keeping a Neutral rating. The positive performance of the Phase 3 THRIVE trial has confirmed that veli met all primary and secondary endpoints and may offer distinct benefits compared to current treatments like Tepezza, thereby reducing the risks associated with Viridian's TED programs, including VRDN-003.
Recent Developments and Financial Insights
Moreover, Viridian has announced a public offering of $150 million for common stock and Series B non-voting convertible preferred stock. These funds are set to enhance clinical development efforts, manage working capital, and support general corporate activities. The offering is being handled by notable financial entities including Jefferies, Goldman Sachs & Co. LLC, Stifel, and RBC Capital Markets.
Financial Position and Market Performance
Recent financial insights put forth by various analysts showcase Viridian's (NASDAQ: VRDN) financial standing and market performance. The company boasts a market capitalization of $1.76 billion, indicative of a solid investor presence. Despite the positive outlook from Goldman Sachs, it is important to consider that Viridian remains in a not profitable status, with a negative P/E ratio of -7.72 as of the second quarter of 2024.
Frequently Asked Questions
What is the current price target for Viridian Therapeutics?
Goldman Sachs has set a price target of $31.00 for Viridian Therapeutics.
What is the THRIVE-2 study?
The THRIVE-2 study is a Phase 3 clinical trial evaluating the effectiveness of veligrotug in treating chronic thyroid eye disease.
How did the Phase III THRIVE trial perform?
The Phase III THRIVE trial met all primary and secondary endpoints, showcasing potential advantages over existing treatments.
Why is veligrotug significant?
Veligrotug is significant due to its promising performance in clinical trials and its potential to offer an alternative to current TED treatments like Tepezza.
What are the future prospects for Viridian Therapeutics?
Viridian’s future prospects depend on successful outcomes from ongoing studies, particularly THRIVE-2, and continued investor interest amid market evaluations.
